Ids Biotech – Business Website
Lyotropic Delivery Systems (LDS) is based on the know-how and many years of research of Prof. Nissim Garti. Garti’s technology led to LDS’s establishment in 2013, and since then has extended its expertise in the field of delivery, developing new and more advanced technologies and strengthening the company’s IP.
An extensive portfolio of early to commercial stage projects
LDS develops, under a licensing agreement, several blockbuster products for an international pharmaceutical company ranked in the top five companies in the industry. Our pipeline includes several projects at both early and late stages, including R&D, pre-clinical, and clinical phases, covered by broad intellectual property rights of several platform and numerous specific patents; some of which are granted and some under examination.
We have licensed our delivery technology to companies in various fields for different active compounds including parenteral (Neoprol, propofol), ophthalmic (OphRx, various molecules) oral (Ananda, cannabinoids), and topical (Nannovate, terbinafine) applications.